GlaxoSmithKline Consumer Healthcare; dba-GlaxoSmithKline recalls Nicorette Lozenge and NicoDerm CQ, nicotine polacrilex system. 189 2mg Mint Flavored Lozenges + 21 31 mg Patches. OTC On
Recalled April 30, 2014 · FDA recall D-1247-2014 · GlaxoSmithKline Consumer Healthcare; dba-GlaxoSmithKline
Hazard
Failed Lozenge Specifications; Lozenges are overly thick, overly soft, and sub and superpotent. · FDA Class III
Units
150 cases
Sold at
U.S. Nationwide
Description
Failed Lozenge Specifications; Lozenges are overly thick, overly soft, and sub and superpotent.
Product
Nicorette Lozenge and NicoDerm CQ, nicotine polacrilex system. 189 2mg Mint Flavored Lozenges + 21 31 mg Patches. OTC Only. GlaxoSmithKlein, 1000 GSK Drive, Moon Township, PA 15108. UPC: 0-03-0766-1480-30-2.
Manufacturer(s)
GlaxoSmithKline Consumer Healthcare; dba-GlaxoSmithKline
Source: U.S. Food and Drug Administration. Official recall notice on fda.gov →